Patrick Collison, one of the funders of this research via the Fast Grants program (https://fastgrants.org/ https://fastgrants.org/), tweeted an excellent summar

Patrick Collison, one of the funders of this research via the Fast Grants program (https://fastgrants.org/ https://fastgrants.org/), tweeted an excellent summary the results a few days ago: https://twitter.com/patrickc/status/1427367934880469010 https://twitter.com/patrickc/status/1427367934880469010 n=1,472 patients; ~1/3 reduction in hospitalization; now pursuing a larger scale trial to replicate the results The actual research results are here: https://www.frontiersin.org/articles/10.3389/fphar.2021.652688/full https://www.frontiersin.org/articles/10.3389/fphar.2021.6526... From the paper, dosage in the trial was: " Participants received 50 mg FLV QD on day 1, then for 2 days 100 mg FLV BID, and then 100 mg FLV TID as tolerated through day 15 and then stopped. " Fluvoxamine has been long off patent. Based on my slap-dash googling of online pharmacies, this treatment would cost under US$10 total. The hypothesized mechanisms of action are the anti-inflammatory, anti-platelet, and potentially antiviral activities which are side effects of Fluvoxamine's psychoactive properties. These mechanisms would counter some of the more serious body responses to the more severe cases of covid.